UCB Shares Promising Results from Phase 3 Study on Fenfluramine
UCB, a prominent global biopharmaceutical company, recently unveiled the results of its GEMZ phase 3 study during a prestigious conference. This study highlights the effectiveness of fenfluramine in significantly reducing the countable motor seizure frequency in patients diagnosed with CDKL5 deficiency disorder (CDD).
Significant Findings from the Clinical Trial
The phase 3 study aimed to address the pressing needs of those affected by CDD. The results showed that fenfluramine achieved the primary endpoint by demonstrating a statistically significant reduction in countable motor seizure frequency (CMSF) compared to a placebo control.
Holistic Improvement in Patient Outcomes
In addition to reducing seizure frequency, the study found that several secondary endpoints were also met. Notably, a substantial number of patients treated with fenfluramine observed at least a 50% reduction in CMSF. Moreover, numerous patients reported clinically meaningful improvements on the Clinical Global Impression–Improvement (CGI-I) scale.
Regulatory Progress on Fenfluramine
Following the encouraging outcomes of this study, UCB plans to submit data for regulatory approval of fenfluramine as a treatment for seizures associated with CDD. This would mark a significant progression in the development of therapies for developmental and epileptic encephalopathies.
Details of the Study Design
The GEMZ study was meticulously designed as a randomized, double-blind, placebo-controlled trial. It involved 87 children and adults, ranging from one to thirty-five years old, all diagnosed with a pathogenic CDKL5 mutation and experiencing uncontrolled seizures. Over a span of 14 weeks, the trial provided illuminating insights into the efficacy of fenfluramine.
Phase 3 Study Results Overview
- Patients receiving fenfluramine experienced a median reduction of 47.6% in CMSF, contrasting sharply with a mere 2.8% reduction in the placebo group.
- After 14 weeks, a remarkable 45.2% of those on fenfluramine achieved a reduction in seizure frequency of at least 50%, compared to just 4.5% in the placebo cohort.
- On the CGI-I scale evaluating improvement, 38.1% of fenfluramine patients were rated as “much improved” or “very much improved,” while only 6.8% of placebo patients reported similar improvements.
- Caregiver reports further indicated that 52.4% of patients on fenfluramine experienced a significant improvement, reinforcing the positive impact of the treatment.
- Moreover, patients on fenfluramine had changes reflected in a mean increase in motor seizure-free days by 6.4 days each month.
Safety Profile and Ongoing Studies
The treatment’s safety profile remained consistent with existing knowledge regarding fenfluramine's effects. The occurrence of treatment-emergent adverse events (TEAEs) was comparable to previous studies in similar conditions, with no new safety concerns arising. Most common TEAEs included fever, diarrhea, and decreased appetite, which were monitored throughout the trial.
Extended Research and Future Directions
UCB remains committed to further research and is conducting an ongoing open-label extension study to assess the long-term efficacy and safety of fenfluramine. This prolonged observation period will provide vital insights into the treatment's effects over time.
Understanding CDKL5 Deficiency Disorder
CDKL5 deficiency disorder is a rare condition characterized by multiple types of drug-resistant seizures which significantly affect neurodevelopment. The disorder occurs due to mutations in the CDKL5 gene and predominantly affects females. Its rarity and severity underline the importance of exploring effective treatment options.
UCB's Commitment to Innovation
UCB’s ongoing dedication to improving the lives of those suffering from severe conditions highlights their mission to innovate in the biopharmaceutical landscape. With revenue exceeding € 6.15 billion in the past year and a presence in about 40 countries, UCB continues to strive toward enhancing patient outcomes through cutting-edge research and therapeutic solutions.
Frequently Asked Questions
What is the primary finding of the GEMZ phase 3 study?
The study demonstrated a significant reduction in countable motor seizure frequency for patients treated with fenfluramine compared to placebo.
What is CDKL5 deficiency disorder?
CDKL5 deficiency disorder is a rare condition marked by various seizure types and significant developmental delays.
What are the next steps for UCB regarding fenfluramine?
UCB plans to submit for regulatory approval of fenfluramine as a treatment for seizures associated with CDKL5 deficiency disorder.
How many patients were involved in the phase 3 study?
The GEMZ study included 87 children and adults with CDKL5 deficiency disorder.
What safety concerns have been noted in the treatment of fenfluramine?
Patients experienced known adverse events consistent with the safety profile established in prior studies, including some serious events, though no new safety issues were detected.
